• Newsletter
  • Search
  • Contacto
  • Home (next newsletter)
  • Home
  • News # 80 | Jun. 2018
  • News # 81 | Jul. 2018
  • News # 82 | Set. 2018
  • News # 83 | Oct. 2018
  • News # 84 | Nov. 2018
  • News # 85 | Dec. 2018
  • News # 86 | Jan. 2019
  • News # 87 | Feb. 2019
  • News # 88 | Mar. 2019
  • News # 89 | Apr. 2019
  • News # 90 | May. 2019
  • News # 91 | Jun. 2019
  • News # 92 | Jul. 2019
  • News # 93 | sep. 2019
  • Newsletters
    • 2008 – 2009
      • News # 1 | nov. 2008
      • News # 10 | nov/dez. 2009
      • News # 2 | dec. 2008
      • News # 3 | jan/fev. 2009
      • News # 4 | mar. 2009
      • News # 5 | abr. 2009
      • News # 6 | mai/jun. 2009
      • News # 7 | jul. 2009
      • News # 8 | ago/set. 2009
      • News # 9 | out. 2009
    • 2010 – 2011
      • News # 11 | jan/fev. 2010
      • News # 12 | mar. 2010
      • News # 13 | abr. 2010
      • News # 14 | mai. 2010
      • News # 15 | jun/jul. 2010
      • News # 16 | ago/set. 2010
      • News # 17 | out/nov. 2010
      • News # 18 | dez. 2010
      • News # 19 | jan/fev. 2011
      • News # 20 | mar/abr. 2011
      • News # 21 | mai/jun. 2011
      • News # 22 | jul/ago. 2011
      • News # 23 | set/out. 2011
      • News # 24 | nov/dez. 2011
    • 2012 – 2013
      • News # 25 | jan. 2012
      • News # 26 | fev/mar. 2012
      • News # 27 | jun. 2012
      • News # 28 | ago. 2012
      • News # 29 | set/out. 2012
      • News # 30 | nov/dez. 2012
      • News # 31 | jan. 2013
      • News # 32 | mar. 2013
      • News # 33 | abr. 2013
      • News # 34 | mai. 2013
      • News # 35 | jun. 2013
      • News # 36 | set. 2013
      •  News # 37 | out. 2013
      • News # 38 | nov/dez. 2013
    • 2014 – 2015
      • News # 39 | jan/fev. 2014
      • News # 40 | mar. 2014
      • News # 41 | abr/mai. 2014
      • News # 42 | jun/jul. 2014
      • News # 43 | set. 2014
      • News # 44 | out/nov. 2014
      • News # 45 | dez. 2014
      • News # 46 | jan. 2015
      • News # 47 | fev. 2015
      • News # 48 | abr. 2015
      • News # 49 | mai. 2015
      • News # 50 | jun. 2015
      • News # 51 | set. 2015
      • News # 52 | out. 2015
      • News # 53 | dez. 2015
    • 2016 – 2017
      • News # 54 | jan. 2016
      • News # 55 | fev. 2016
      • News # 56 | mar. 2016
      • News # 57 | abr. 2016
      • News nº 58 | may 2016
      • News # 59 | jun. 2016
      • News # 60 | jul. 2016
      • News # 61 | set. 2016
      • News # 62 | out. 2016
      • News # 63 | nov/dez. 2016
      • News # 64 | jan. 2017
      • News # 65 | fev. 2017
      • News # 66 | mar. 2017
      • News # 67 | apr. 2017
      • News # 68 | may 2017
      • News # 69 | jun. 2017
      • News # 70 | jul. 2017
      • News # 71 | set. 2017
      • News # 72 | out. 2017
      • News # 73 | nov. 2017
      • News # 74 | dez. 2017
    • 2018
      • News # 75 | jan. 2018
      • News # 76 | fev. 2018
      • News # 77 | mar. 2018
      • News # 78 | abr. 2018
      • News #79 | May 2018
  • Subscribe Newsletter
My Company
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News # 73 | nov. 2017
      • News # 72 | out. 2017
      • News # 70 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto
Main Menu
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News # 73 | nov. 2017
      • News # 72 | out. 2017
      • News # 70 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto

Role of the B-type natriuretic peptide in the classification of ischemic Cerebrovascular Accidents

By etavares On 31 December, 2010 Open Space | 2010 Comments Off on Role of the B-type natriuretic peptide in the classification of ischemic Cerebrovascular Accidents No tags

It is not possible to establish an etiology in around 30-40% of ischemic Cerebrovascular Accidents (CVA). This happens frequently, even following exhaustive clinical research. It is possible that a fraction of these CVAs, called cryptogenic strokes, occurs after an episode of paroxysmal atrial fibrillation (AF), which cannot be documented. AF-related CVAs are generally serious, with an estimated mortality of 50% in the first year. Recurrence rate is high and leads to morbidity and significant costs. Correct identification of a cardioembolic etiology in this type of patients is important, since it has been demonstrated that oral anticoagulants, compared with antiaggregating therapy, reduces the risk of recurring CVAs in patients with nonvalvular AF, and may be associated with less serious CVAs in case of recurrence.

Current complementary diagnostic means have a low capacity for detecting paroxysmal AF. Despite the Holter test being superior to the electrocardiogram, in a systematic review, Holter’s capacity (24-72 hours) to detect paroxysmal FA was 4.6%. Longer monitoring (4-7 days) has detected AF in a further 8% of patients. Prolonged 7-day long recordings, at 0 and 6 months following a CVA, have detected AF in 14% of patients.

Accordingly, it is necessary to consider alternative ways of detecting an eventual cardioembolic etiology in cryptogenic CVA. The importance of correctly identifying a CVA as cardioembolic has led to the possibility of using biomarkers in its diagnostic.

Previous studies have demonstrated a rise in the serum concentrations of the Brain Natriuretic Peptide (BNP) during the acute phase of ischemic CVA when compared with those found in controls and with the cut-off points established for heart failure. The BNP is a neurohormone that has been studied and disseminated as a natriuretic cardiac hormone. However, recent studies suggest it may play an important role in the physiopathology of acute CVA.
In chemical terms, it is a peptide initially produced as a prohormone called pro-BNP. Pro-BNP is subsequently divided into biologically active BNP and N-terminal-proBNP (NT-proBNP), which has no biological activity.

Most tests measure NT-proBNP, and until now the production of BPN has been attributed to two areas: the brain and, above all, the heart. Here, myocyte stretching is the main stimulus for BNP synthesis and secretion. Under a normal physiological state, the auricula is the main place for cardiac production. Catecholamine, angiotensin II and endothelin may stimulate the secretion of BNP, through paracrine or endocrine mechanisms. It is presumed that NT-proBNP is eliminated from circulation through kidney excretion. The biological effects of BNP include natriuresis, diuresis, vasodilation, inhibition of the do renin-angiotensin-aldosterone axis and the sympathetic nervous system. This peptide is currently used as a marker of left ventricular and prognostic dysfunction in patients with congestive heart failure (CHF) and with acute coronary syndromes. High plasmatic levels of NT-proBNP were noted in patients suffering from kidney failure, essential hypertension and disrhythmias such as AF. Advanced age and low levels of haemoglobins are associated to increased plasmatic levels of BNP.

Despite BNP having been firstly identified in brain tissue, current information about this natriuretic peptide in cerebral-vascular disease is limited. Some works to date have shown a sharp rise in NT-pro-BNP during the acute phase of ischemic CVA.

Four possibilities have been put forward for increasing NT-proBNP during acute ischemic CVA:

– These patients often suffer from heart failure, and BNP increase might reflect ventricular dysfunction.
– It might be related to AF, which is a risk factor for CVA and a cause for BNP increase.

– As the brain is a place for BNP production, it might occur after lesion in the cerebral parenchyma.

– Due to its sympathetic-inhibitive effects, BNP increase may emerge as a response to increased sympathetic activity.

In a previous work carried out as part of an original dissertation in the Master Degree in Neurosciences at the Faculty of Medicine of the University of Lisbon (FMUL), we attempted to determine whether NT-proBNP increase in the acute phase of ischemic CVA might have a cardiac origin. The results suggested that the increase in the serum concentration of NT-proBNP, which occurs in the context of CVA, has a cardiac origin. We noted that patients with ischemic cardioembolic CVA had statistically significant higher average concentrations of NT-proBNP compared with patients with non-cardioembolic ischemic CVA.

No association was found between the serum concentration of NT-proBNP and the extent and location of the CVA, or blood pressure values. NT-proBNP showed a very good capacity to diagnose cardioembolic CVA associated with atrial fibrillation in the first 72 hours after ischemic CVA, with the ROC curve analysis showing two cut-off points with great sensitivity and specificity.

To identify a CVA of cardioembolic etiology, a value of area below the AUC curve of 0.77±0.06 was achieved. The cut-off point with the greatest specificity and sensitivity was established at 265.50 pg/mL (71.4% and 74%, respectively). To identify a CVA of cardioembolic etiology with AF, an AUC of 0.92 ± 0.03 was obtained. The NT-proBNP value established as a cut-off point was 265.50 pg/mL (sensitivity 94.4%, specificity 72.9%) and 912.0 pg/mL (sensitivity 55.5%, specificity 97.9%).

A further study in a different sample including a higher number of patients is now in progress, in order to validate the established cut-off points. The objective is also to identify possible sources of variation in NT-proBNP, and to establish the profile for temporal evolution of NT-proBNP following ischemic CVA. The work is supervised by Professor José Ferro and Professor Dulce Brito, with the collaboration of Dr. Sampaio Matias and of the doctors from the Cerebrovascular Accidents Unit of Santa Maria Hospital Neurology Service.
Ana Catarina Fonseca
Neurology Service
Santa Maria Hospital
catarinagfonseca@gmail.com

Share

Search

Index - News # 18 | dez. 2010
 Editorial Note
 Pessoa Prize awarded to Professor Maria do Carmo Fonseca
 Five prizes awarded to IMM researchers in one month
 Interview with Professor José Ferro – Full Professor in Neurology and Head of the Neurology Unit
 Interview with Professor Isabel Pavão Martins – President of the Portuguese Society of Neurology
 Debate about Oncology at the Second International Symposium of the Harvard Medical School Program – Portugal
 Education for Science” brings together Students, Lecturers and Researchers
 8th IST / FMUL Biomedical Engineering Meeting 2010-2011
 Interview with Professor José Pedro Sousa Dias
 Campaign “Small and Ecological”
 Egas Moniz Museum
 Um pouco de História e bibliografia selectiva de Egas Moniz (1874-1955)
 Conferência “Universidade Verde”Carla Reis
 Communication inside the Organisation
 Resultados da Campanha do Banco Alimentar Contra a Fome SPUL/FMUL
 Livro do Mês
 7th AstraZeneca Foundation /Faculty of Medicine of the University of Lisbon Research Scholarship
 21st European Students’ Conference
 Scientific Research Projects 2009/2010 – Neurology Area
 Lecturers’ Participation in Academic Examination Panels in other institutions (by 9 December 2010)
 Academic examinations at the Faculty of Medicine of the University of Lisbon
 Publications FMUL/HSM/IMM
 Bags and Rucksacks: “weights” today and “burdens” tomorrow (PART II)
 Efficacy of intensive speech therapy in aphasic patients due to vascular causes
 Cerebral venous and sinus thrombosis
 The research project LADIS – LeukoAraisosis and DISability
 Role of the B-type natriuretic peptide in the classification of ischemic Cerebrovascular Accidents
 Apathy in Acute Stroke and Personality Disturbance Secondary to Stroke
 Acute Brain Ischemia, Hypothermia and Hybernation: The Role of Oxidative Fosforilation Inhibitors
 Science and Health Research
 Indicators of the University Clinic of Neurology
My Company

100 AnosPropriedade e Edição: Faculdade de Medicina da Universidade de Lisboa NIPC: 502662875  Periodicidade: Mensal  Diretor: Prof. Doutor Fausto J. Pinto Conselho Editorial: Prof. Doutor Fausto J. Pinto, Profª. Doutora Ana Sebastião, Prof. Doutor Mamede de Carvalho, Prof. Doutor António Vaz Carneiro, Prof. Doutor Miguel Castanho, Dr. Luís Pereira  Equipa Editorial:  Ana Raquel Moreira, Cristina Bastos, Isabel Varela, Joana Sousa, Maria de Lurdes Barata, Rui Gomes, Sónia Teixeira  Colaboração:  Gabinete de Relações Públicas, Internacionais e Comunicação  Versão Inglesa: AP|PORTUGAL- Language Services  Conceção: Metatexto, Lda. e-mail: news@medicina.ulisboa.pt  Sede do Editor e Sede da Redação: Avenida Prof. Egas Moniz, 1649-028 Lisboa Estatuto Editorial Anotado na ERC 

  • Increase Font
  • Decrease Font
  • Black & White
  • Inverse Colors
  • Highlight Links
  • Regular Font
  • Reset
Real Accessability